Abstracts tagged "Interferons and systemic lupus erythematosus (SLE)"

Abstract Number: 642 • 2012 ACR/ARHP Annual Meeting
Effects of Treatment On the Expression of CCL2 and CXCL10 in Systemic Lupus Erythematosus Patients
Paul R. Dominguez-Gutierrez¹, Angela Ceribelli¹, Minoru Satoh², Eric S. Sobel³, Westley H. Reeves⁴ and Edward K.L. Chan¹, ¹Oral Biology, University of Florida, Gainesville, FL, ²Medicine, University of Florida, Gainesville, FL, ³Medicine/Div of Rheumatology, University of Florida, Gainesville, FL, ⁴Rheumatology & Clinical Imm, University of Florida, Gainesville, FL
Background/Purpose: Several candidate biomarkers for Systemic Lupus Erythematosus (SLE) have been reported including STAT1, ADAR, CCL2, CXCL10, and miR-146a. This study examines the effects of…
Abstract Number: 620 • 2012 ACR/ARHP Annual Meeting
Development of A Quantitative PCR Method to Determine Interferon Signature Metric Status in SLE Patients: Distribution and Clinical & Serological Associations in Two Lupus Clinical Trials
Bruce C. Richardson¹, William P. Kennedy², John C. Davis Jr.², R. Maciuca², A. Morimoto², J. M. McBride², Alexander R. Abbas², Timothy W. Behrens² and Michael J. Townsend³, ¹Internal Medicine, University of Michigan, Ann Arbor, MI, ²Genentech, Inc, South San Francisco, CA, ³Genentech, South San Francisco, CA
Background/Purpose: Elevated and coordinated expression of multiple Interferon-regulated genes (IRGs) in peripheral blood cells is present in most systemic lupus erythematosus (SLE) patients. Here we…
Abstract Number: 626 • 2012 ACR/ARHP Annual Meeting
The Interferon Alpha Gene Signature Is Not Associated with Nor Does It Predict Progression of Coronary Artery Calcium (CAC) or Carotid Intima-Media Thickness (IMT) in Systemic Lupus Erythematosus (SLE)
Adnan Kiani¹, Hong Fang¹, Jie Xu², Ehtisham Akhter³ and Michelle Petri¹, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Div of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Accelerated atherosclerosis is the major cause of late mortality in SLE. Interferon alpha plays a role in atherosclerosis by deleting endothelial progenitor cells and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].